Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not reduce the risk for incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase 4 (DPP-4 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback